UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 1)

Under the Securities Exchange Act of 1934

TONIX PHARMACEUTICALS HOLDING CORP.

(Name of Issuer)
Common Shares
(Title of Class of Securities)
890260201
(CUSIP Number)
April 5, 2017
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☑ Rule 13d-1(c) ☐ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP	No. 890260 2	201	13G/A	Page 2 of 9 Page	
1.			ORTING PERSONS CATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)		
	Rosalind A	dvisor	s. Inc.		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) (b) (c) (d) (e) (e) (f) (f) (f) (f) (f) (g) (g				
3.	SEC USE O	ONLY			
4.	CITIZENS	HIP O	R PLACE OF ORGANIZATION		
	ONTARIO	, CAN	ADA		
	DED 05	5.	SOLE VOTING POWER 0		
SH. BENEF	IBER OF LARES FICIALLY NED BY ACH ORTING ON WITH	6.	SHARED VOTING POWER 594,077		
EA REPO		7.	SOLE DISPOSITIVE POWER 0		
LKSC	71 . W1111	8.	SHARED DISPOSITIVE POWER 594,077		
9.	AGGREGA 594,077	ATE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) □				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9% ¹				
12.		REPO	RTING PERSON (see instructions)		

 1 This percentage is calculated based upon 5,960,814 shares of the Issuer's common stock outstanding as of April 4, 2017.

CO

CUSIP 1	No. 8902602	01	13G/A	Page 3 of 9 Page
			ORTING PERSONS CATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Steven Sala	mon		
			PROPRIATE BOX IF A MEMBER OF A GROUP	
	(see instruct	ions)		
	(a) □ (b) □			
3.	SEC USE C	NLY		
4.	CITIZENSI	HIP O	R PLACE OF ORGANIZATION	
	ONTARIO,	CAN	ADA	
		5.	SOLE VOTING POWER	
			0	
	BER OF	6.	SHARED VOTING POWER	
	ARES ICIALLY			
	ED BY		594,077	
	СH	7.	SOLE DISPOSITIVE POWER	
_	RTING		0	
PERSO	N WITH	8.	SHARED DISPOSITIVE POWER	
			594,077	
9.	AGGREGA	TE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	594,077			
		THE A	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
	(see instruct	tions)		
11.	PERCENT	OF CI	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	$9.9\%^{2}$			
		EPOF	TING PERSON (see instructions)	
	Di			

 $^{^2}$ This percentage is calculated based upon 5,960,814 shares of the Issuer's common stock outstanding as of April 4, 2017.

CUSIP 1	No. 8902602	01	13G/A	Page 4 of 9 Page
			ORTING PERSONS CATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Rosalind Ma	ster F	und L.P.	
2.			PROPRIATE BOX IF A MEMBER OF A GROUP	
	(see instruct	ions)		
	(a) □ (b) □			
3.	SEC USE O	NLY		
4.	CITIZENSH	IIP O	R PLACE OF ORGANIZATION	
	CAYMAN I	SLA	NDS	
		5.	SOLE VOTING POWER	
			0	
	BER OF	6.	SHARED VOTING POWER	
	ARES ICIALLY			
	ED BY		167,352	
	СH	7.	SOLE DISPOSITIVE POWER	
	RTING		0	
PERSO	N WITH	8.	SHARED DISPOSITIVE POWER	
			167,352	
9.	AGGREGA	TE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	167,352			
10.		THE	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
	(see instruct			
11.	PERCENT (OF CI	LASS REPRESENTED BY AMOUNT IN ROW (9)	
	2.8% ³			
12.	TYPE OF R	EPOF	RTING PERSON (see instructions)	
	PN			

³ This percentage is calculated based upon 5,960,814 shares of the Issuer's common stock outstanding as of April 4, 2017.

PN

⁴ This percentage is calculated based upon 5,960,814 shares of the Issuer's common stock outstanding as of April 4, 2017.

Item 1.

- (a) Name of Issuer: TONIX PHARMACEUTICALS HOLDING CORP.
- (b) Address of Issuer's Principal Executive Offices 509 Madison Avenue, Suite 306 New York, New York 10022, United States

Item 2.

(a) Name of Person Filing

Rosalind Advisors, Inc. ("Advisor" to RCP & RMF)
Rosalind Master Fund L.P. ("RMF")
Rosalind Capital Partners L.P. ("RCP")
Steven Salamon ("President")
Steven Salamon is the portfolio manager of the Advisor which advises RCP & RMF.

(b) Address of the Principal Office or, if none, residence

Rosalind Advisors, Inc. 175 Bloor Street East Suite 1316, North Tower Toronto, Ontario M4W 3R8 Canada

Rosalind Master Fund L.P. P.O. Box 309 Ugland House, Grand Cayman KY1-1104, Cayman Islands

Rosalind Capital Partners L.P. 175 Bloor Street East Suite 1316, North Tower Toronto, Ontario M4W 3R8 Canada

Steven Salamon 175 Bloor Street East Suite 1316, North Tower Toronto, Ontario M4W 3R8 Canada

(c) Citizenship

Rosalind Advisors, Inc.: Ontario, Canada Rosalind Master Fund L.P.: Cayman Islands Rosalind Capital Partners L.P.: Ontario, Canada Steven Salamon: Ontario, Canada

(d) Title of Class of Securities Common Stock

(e) CUSIP Number 890260201

Item 3.	If t	his statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:		
(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).		
(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).		
(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).		
(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).		
(e)		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);		
(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);		
(g)		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);		
(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);		
(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);		
(j)		Group, in accordance with §240.13d-1(b)(1)(ii)(J).		
Item 4.	Ow	nership.		
Provide 1.	the	following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item		
(a)	Am	ount beneficially owned:		
	Ros	salind Master Fund L.P. is the record owner of 156,150 shares, and warrants to acquire 11,202 shares of common stock.		
	Ros	salind Capital Partners L.P. is the record owner of 397,758 shares, and warrants to acquire 28,967 shares of common stock.		
	Rosalind Advisors, Inc. is the investment advisor to RCP and RMF and may be deemed to be the beneficial owner of shares held by RCP and RMF. Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RCP and RMF. Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.			
(b)	Per	cent of class:		
		Rosalind Advisors, Inc. – 9.9%		
		Rosalind Master Fund L.P. -2.8%		
		Rosalind Capital Partners L.P. – 7.1%		
		Steven Salamon – 9.9%		

- (c) Number of shares as to which the person has:
 - (i) Shared power to vote or to direct the vote

Rosalind Advisors, Inc. – 594,077 Rosalind Master Fund L.P. – 167,352 Rosalind Capital Partners L.P. – 426,725 Steven Salamon – 594,077

- (ii) Sole power to dispose or to direct the disposition of -0
- (iii) Shared power to dispose or to direct the disposition of

Rosalind Advisors, Inc. – 594,077 Rosalind Master Fund L.P. – 167,352 Rosalind Capital Partners L.P. – 426,725 Steven Salamon –594,077

Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Instruction. Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Item 7-9. Not Applicable

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

A/7/2017
Date

/s/ Steven Salamon
Signature

Steven Salamon/President Rosalind Advisors, Inc.
Name/Title

Joint Filing Agreement

The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of TONIX PHARMACEUTICALS HOLDING CORP. is filed jointly, on behalf of each of them.

Rosalind Advisors, Inc.

By: /s/ Steven Salamon Name: Steven Salamon Title: President

Rosalind Master Fund L.P.

By: /s/ Mike McDonald

Name: Mike McDonald

Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

Rosalind Capital Partners L.P.

By: /s/ Steven Salamon Name: Steven Salamon

Title: President, Rosalind Advisors, Inc.

By: /s/ Steven Salamon Name: Steven Salamon